This piece by News Editor Matt Pilon originally appeared in the Hartford Business Journal December 22, 2016.
A partnership between a Farmington inventor and an Arizona medical company is progressing with the recent launch of a Phase I clinical trial to test the safety of a medical device that aims to treat Alzheimer’s disease.
This month, NeuroEM started a two-month clinical trial for a related device it developed.
NeuroEM CEO Gary Arendash, a neuroscientist, said the two companies aim to combine their technologies.
NeuroEM’s license with Knight “will allow both companies to combine their innovations to ultimately create the optimum therapeutic approaches against Alzheimer’s,” Arendash said in a statement.
“We look forward to our continued combined R&D as our clinical trials roll out,” he said.
Patients in the trial, which involves two Phoenix-based institutes, will receive treatments at home.